Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quiklean
- Development stage
- Phase 3
- Lead developer
- Universal Integrated Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quiklean is an oral pharmaceutical drug indicated for bowel preparation prior to colonoscopy. It is a combination drug containing sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. These active ingredients function as saline laxatives, drawing water into the intestinal lumen through osmotic action, thereby increasing stool volume and promoting catharsis for effective bowel cleansing. It is administered in tablet form.
- Brand names
- Quiklean
02
Targets
PiT2 (Sodium-dependent phosphate transporter 2)
Beyond the preview
Go deeper on Quiklean.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quiklean.